GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Cefazolin

GlobalRPh source pageBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Ancef / Kefzol

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

UCSF - cefazolin

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
CrCl in mL/min where specified; no equation inferred.

Dosing / renal protocol and limits

Limits that apply to these rows

Exactly 30 is not assigned. Deep MSSA infection with clinical instability may need individualized higher dosing. Keep dialysis stability and the 72-hour gap attached to the alternative.

Uncomplicated Gram-positive infection - IV
CrCl, mL/minSource-specific dose / instruction
>301 g every 8 hours
10-291 g every 12 hours
<101 g every 24 hours
Complicated Gram-positive or Gram-negative infection - IV
CrCl, mL/minSource-specific dose / instruction
>302 g every 8 hours
10-292 g every 12 hours
<101 g every 24 hours
Dialysis guidance - separate source-specific schedules
UCSF cefazolin dialysis
Dialysis setting / indicationSource-specific schedule
IHD2 g initially and after HD
Stable thrice-weekly IHD alternative2 g / 2 g / 3 g after HD; 3 g precedes the 72-hour gap
CVVHD2 g IV every 12 hours
Read the retained text before reformatting

For CrCl >30 / 10-29 / <10 mL/min:

  • Uncomplicated Gram-positive infection: 1 g IV every 8 / 12 / 24 hours.
  • Complicated Gram-positive or Gram-negative infection: 2 g IV every 8 hours / 2 g every 12 hours / 1 g daily.

Deep MSSA infection with clinical instability may need individualized higher dosing.

IHD: 2 g initially and after HD. Stable thrice-weekly dialysis permits the alternative 2 g / 2 g / 3 g post-HD sequence, with 3 g preceding the 72-hour interdialytic gap. CVVHD: 2 g IV every 12 hours.

Exactly 30 mL/min is not assigned by the published >30 and 10-29 columns.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/cefazolin

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - cefazolin

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Professional source

Stanford adult Cefazolin

Adult institutional dosing; not a manufacturer-label replacement.

Method: Not stated in selected source.

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeStanford adult CefazolinUCSF - cefazolin
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The source summary says "Maximum interval: q8h" whereas its package-insert paragraph specifies at least 8-hour intervals. This wording conflict is preserved for review.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/cefazolin/

Usual Dosing (Adults)

[Usual]: 500mg to 1g IV q8h.

[Moderate to severe]: 500mg-1 gram q6-8h.

[life-threatening]: 1-1.5g q6h.

[Maximum dosage/day]: 12 grams.

DOSAGE AND ADMINISTRATION - Usual Adult Dosage

Type of infectionDoseFrequency
Moderate to severe infections500 mg to 1 gramEvery 6 to 8 hrs
Mild infections caused by susceptible gram-positive cocci250 mg to 500 mgEvery 8 hours
Acute, uncomplicated urinary tract infections1 gramEvery 12 hours
Pneumococcal pneumonia500 mgEvery 12 hours
Severe, life-threatening infections (e.g., endocarditis, septicemia)1 gram to 1.5 gramsEvery 6 hours

In rare instances, doses of up to 12 grams of ANCEF per day have been used.

GRPH-cefazolin-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

[CRCL >55 ml/min]: no change.

[35-54 ml/min]: Maximum interval: q8h. 500mg-1.5g q8h.

[11-34 ml/min]: 500mg-1.5g x 1, then 0.5-1 gram q12h.

[<10 ml/min]: 500 mg-1 gram q18-24h.

Dosage Adjustment for Patients With Reduced Renal Function

ANCEF may be used in patients with reduced renal function with the following dosage adjustments: Patients with a creatinine clearance of 55 mL/min or greater or a serum creatinine of 1.5 mg % or less can be given full doses. Patients with creatinine clearance rates of 35 to 54 mL/min or serum creatinine of 1.6 to 3.0 mg % can also be given full doses but dosage should be restricted to at least 8 hour intervals. Patients with creatinine clearance rates of 11 to 34 mL/min or serum creatinine of 3.1 to 4.5 mg % should be given 1/2 the usual dose every 12 hours. Patients with creatinine clearance rates of 10 mL/min or less or serum creatinine of 4.6 mg % or greater should be given 1/2 the usual dose every 18 to 24 hours. All reduced dosage recommendations apply after an initial loading dose appropriate to the severity of the infection.

GRPH-cefazolin-02 · Source section: Renal DosingRenal section finder

Hemodialysis

500 mg-1 gram IV q24h. (Give dose post-dialysis on dialysis days.) PD: 500 mg q12h.

GRPH-cefazolin-03 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

Stanford adult Cefazolin

Open original reference

Open / share this exact local source

Stanford Antimicrobial Safety and Sustainability Program · Adult institutional dosing; not a manufacturer-label replacement.

Renal method: Not specified in this summary.
Source date: Antibiotic Subcommittee approved August 2026
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Source-specific regimen

Limits that apply to these rows

Retained Stanford protocol. Do not mix with another institution's dialysis schedule.

Mild adult infection - IV
CrCl, mL/minSource-specific dose / instruction
>301 g every 8 hours
10-301 g every 12 hours
<101 g every 24 hours
Moderate/severe adult infection - IV
CrCl, mL/minSource-specific dose / instruction
>302 g every 8 hours
10-302 g every 12 hours
<102 g every 24 hours
Dialysis guidance - separate source-specific schedules
Stanford cefazolin dialysis
Dialysis setting / indicationSource-specific schedule
HD1 g daily, after dialysis on treatment days
CRRT2 g every 12 hours
Read the retained text before reformatting

Adult IV, CrCl >30 / 10-30 / <10 mL/min: mild infections 1 g every 8 / 12 / 24 hours; moderate/severe 2 g at those intervals. HD: 1 g daily, after dialysis on treatment days. CRRT: 2 g every 12 hours.

cefazolin:stanford-cefazolin-1 · Source locator: PDF page 2, Cefazolin row

Source identity and provenance
Source
https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/antimicrobial-dosing-protocols/SHC-ABX-Dosing-Guide.pdf
Retrieved
2026-09-05
Source date/version
Antibiotic Subcommittee approved August 2026
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
046be365c61523c91e46daa4da8acf0d69c142f14720983f7f5537db184b0722
Professional

UCSF - cefazolin

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Exactly 30 is not assigned. Deep MSSA infection with clinical instability may need individualized higher dosing. Keep dialysis stability and the 72-hour gap attached to the alternative.

Uncomplicated Gram-positive infection - IV
CrCl, mL/minSource-specific dose / instruction
>301 g every 8 hours
10-291 g every 12 hours
<101 g every 24 hours
Complicated Gram-positive or Gram-negative infection - IV
CrCl, mL/minSource-specific dose / instruction
>302 g every 8 hours
10-292 g every 12 hours
<101 g every 24 hours
Dialysis guidance - separate source-specific schedules
UCSF cefazolin dialysis
Dialysis setting / indicationSource-specific schedule
IHD2 g initially and after HD
Stable thrice-weekly IHD alternative2 g / 2 g / 3 g after HD; 3 g precedes the 72-hour gap
CVVHD2 g IV every 12 hours
Read the retained text before reformatting

For CrCl >30 / 10-29 / <10 mL/min:

  • Uncomplicated Gram-positive infection: 1 g IV every 8 / 12 / 24 hours.
  • Complicated Gram-positive or Gram-negative infection: 2 g IV every 8 hours / 2 g every 12 hours / 1 g daily.

Deep MSSA infection with clinical instability may need individualized higher dosing.

IHD: 2 g initially and after HD. Stable thrice-weekly dialysis permits the alternative 2 g / 2 g / 3 g post-HD sequence, with 3 g preceding the 72-hour interdialytic gap. CVVHD: 2 g IV every 12 hours.

Exactly 30 mL/min is not assigned by the published >30 and 10-29 columns.

RDM30-011-cefazolin-1 · Source locator: UCSF - cefazolin; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/cefazolin
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e40b67b76c05828e2f913d65de9d20679143486edaf7cb92fc308cf32eab98c5

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/cefazolin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
c29d10fbd2e984bbfec66f9421278289b110cef427a7359336875c5295a14d72
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report